$5.7 Billion Take-Private Deal

KKR & Co. (KKR) has entered into a definitive agreement to acquire Integer Holdings Corporation (ITGR), a medical device contract development and manufacturing organization (CDMO), for approximately $5.7 billion. The purchase price consists of approximately $4.3 billion in cash payable at closing, plus Integer's net debt, and does not include any clinical, regulatory, or royalty milestones. Upon completion of the transaction, subject to shareholder and regulatory approvals and customary closing conditions, Integer will be delisted from the New York Stock Exchange. This deal reflects KKR's preference for the cash flows generated by medical device manufacturing, which are supported by regulatory barriers and recurring orders, over the risks associated with new drug development.

Cardiovascular Manufacturing Capabilities are Key

Integer designs and manufactures catheters, guidewires, batteries, and implantable components, as well as finished devices, for cardiovascular, vascular, cardiac rhythm management, and neurostimulation applications. In 2025, the company generated $1.85 billion in revenue, an 8% increase, and adjusted EBITDA of $423 million, an 11.6% increase. Cardiovascular and vascular revenue accounted for $1.17 billion, a 17% increase. The miniaturization and increasing complexity of electrophysiology and neurovascular devices have driven demand for outsourced manufacturing, making Integer's precision machining, catheter assembly, and implantable power technology valuable assets.

Growing Market and Competitive Landscape

The global medical device contract manufacturing market is expected to grow from $96.4 billion in 2025 to $155.2 billion in 2030, representing a compound annual growth rate of 10%. Integer competes with Jabil (JBL), TE Connectivity (TEL)'s Creganna Medical, Resonetics, Cirtec Medical, and Viant for design, precision component, and finished device manufacturing contracts. The competition is not based on efficacy compared to existing standard-of-care treatments or competing drug candidates, but rather on the quality, yield, delivery timelines, and compliance with FDA Quality System Regulations (QSR) that medical device OEMs require.

Valuation and Execution Risks

The $5.7 billion enterprise value represents a multiple of approximately 3.1 times Integer's 2025 revenue and 14.2 times its adjusted EBITDA, reflecting a premium valuation for a high-growth medical device CDMO. As of the end of 2025, Integer had $1.19 billion in net debt and a net leverage ratio of 3.0 times adjusted EBITDA, so the success of the acquisition will depend on KKR's ability to manage financing costs and capital allocation. From a regulatory perspective, the transaction is not contingent on the FDA, EMA, or PMDA approval of specific products or advisory committee (AdComm) votes; instead, the key steps are regulatory clearance and shareholder approval. Customer dual-sourcing and in-house manufacturing are downside risks, but the expansion of cardiovascular and neurovascular device manufacturing capacity will improve OEM time-to-market and patient supply reliability.